Catalog No.
Product Name
Application
Product Information
Citations
-
DDP-4 inhibitor
Sitagliptin phosphate is an anti-diabetic (antihyperglycemic) drug of the dipeptidyl peptidase-4 (DPP-4) class. Inhibition of the enzyme DPP-4 is thought to increase Glucagon-like peptide-1 (GLP-1) which inhibits glucagon release , stimulates the insulin release and lowers blood glucose. -
DPP-4 Inhibitor
Saxagliptin (BMS-477118) is a new dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 50 nM.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
- OHE El-Shoubashy, .et al. , JPC, 2020, 33, 59-70
- Sato T, .et al. , Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
- Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
- Koyani CN, .et al. , Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968
-
DPP-4 Inhibitor
Linagliptin is a DPP-4 inhibitor, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).- Fen Zhuge, .et al. , Exp Neurol, 2024, Mar:373:114689 PMID: 38199510
-
DPP-IV Inhibitor
Vildagliptin is a dipeptidyl peptidase-4 (CD26) inhibitor.- Cecilia Villegas-Novoa, .et al. , Anal Chem, 2022, 94(27):9648-9655 PMID: 35758929
- Prodipine, a diphenyl-phosphonate derivative. The IC50s of Prodipine for purified and plasma Dipeptidyl peptidase IV (DPP IV) from the rabbit are 4.5 μM and 30 μM, respectively.
-
DPP-4 inhibitor
Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5). -
DPP-4 inhibitor
Alogliptin Benzoate is a dipeptidyl-peptidase-4 (DPP 4) inhibitor -
DPP-4 inhibitor
Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). -
DPP-4 inhibitor
Anagliptin is a potent and selective DPP-4 inhibitor(IC50= 3.8 nM); > 10 fold less potent for DPP-8 and DPP-9. -
DPP-4 inhibitor
Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. -
DPIV and DP8/9 inhibitor
DPP-IV-IN-2 is an inhibitor of both dipeptidyl peptidase IV (DPIV) and DP8/9 with IC50s of 0.1 and 0.95 μM, respectively. -
DPP-IV inhibitor
Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM). -
DPP-4 inhibitor
Talabostat mesylate is a potent, nonselective and orally available dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 0.18 nM. -
DPP-4 inhibitor
Trelagliptin is a highly selective, long-acting DPP-4 inhibitor.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
-
DDP-4 inhibitor
Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.- Hae Jin Kim, .et al. , Korean J Physiol Pharmacol, 2018, Nov; 22(6): 713-719 PMID: 30402032
- Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
-
DPP-4 inhibitor
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. -
DPP-4 inhibitor
DPPI 1c hydrochloride is a dicyanopyrrolidine compound that acts as a slow-binding and active site-targeting inhibitor of CD26 (DPP 4), with an IC50 = 106 nM and little activity against DPP II, DPP III, DPP VIII, DPP IX, FAP, or APP even at concentrations as high as 30 μM. -
DPP-4 inhibitor
PK 44 phosphate is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV) with an IC50 value of 15.8 nM. -
DPP-4 inhibitor
NVP DPP 728 dihydrochloride is a potent and orally active inhibitor of dipeptidyl peptidase (DPP)-IV with Ki and IC50 values of 11 nM and 14 nM, respectively. -
DPP-4 inhibitor
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. -
DPP-II inhibitor
UAMC 00039 dihydrochloride is a potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM). Exhibits selectivity for DPP-II against DPP-9, DPP-8 and DPP-IV (IC50 values are 78.6, 142 and 165 μM, respectively). -
DPP4 inhibitor
Saxagliptin H2O(BMS477118 H2O) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM and Ki of 1.3 nM. -
DPP-4 inhibitor
Retagliptin Phosphate is pharmaceutical composition of DPP-4 inhibitor for treating type-2 diabetes. -
DPP4 inhibitor
Gemigliptin is a highly selective dipeptidyl peptidase 4 (DPP4) inhibitor with a KD of 7.25 nM.- Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
-
DPP-4 inhibitor
Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. -
DPP IV inhibitor
Diprotin A (TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV). -
DPP-IV inhibitor
Gosogliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-IV). -
DPP4 inhibitor
Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus. -
DPP4 inhibitor
Vildagliptin (LAF237 dihydrate;NVP-LAF 237 dihydrate) is a dipeptidyl peptidase 4 (DPP4) inhibitor that delays the degradation of glucagon-like peptide-1 (GLP-1). - HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity.
-
DPP4 Inhibitor
DPP4-In hydrochloride is a selective inhibitor of dipeptidyl peptidase 4 (DPP4), an enzyme that plays a critical role in glucose metabolism and immune regulation. By inhibiting DPP4, this compound can effectively increase the levels of active incretin hormones, which may contribute to improved glycemic control. DPP4-In hydrochloride is primarily utilized in diabetes research and can aid in the investigation of metabolic disorders and potential therapeutic strategies for type 2 diabetes. -
DPP4 Inhibitor
Evogliptin is an orally active inhibitor of DPP4 (dipeptidyl peptidase-4), demonstrating notable and sustained hypoglycemic effects in murine models. In addition to its antidiabetic properties, Evogliptin exerts effects by inhibiting the production of inflammatory and fibrotic signals in hepatocytes through the induction of autophagy. This compound is particularly relevant for research applications related to type 2 diabetes, osteoporosis, renal impairment, and chronic liver inflammation. -
DPP4 Inhibitor
(Rac)-Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP4), exhibiting an IC50 of 19 nM in Caco-2 cell extracts. This compound plays a significant role in the modulation of glucose metabolism, making it relevant for diabetes research. Its ability to enhance insulin secretion and decrease glucagon levels underscores its potential applications in studying metabolic disorders and developing therapeutic strategies for type 2 diabetes. -
DPP-4 Inhibitor
PB01 is a selective DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively reduces high glucose-induced reactive oxygen species (ROS) production and mitochondrial superoxide generation while significantly decreasing cellular DPP-4 expression. In vivo studies demonstrate that PB01 can lower blood glucose levels in diabetic mice, indicating its potential therapeutic application. Furthermore, PB01 exhibits minimal cytotoxicity at a concentration of 100 μM, making it a promising candidate for diabetes-related research. -
DPP-IV Inhibitor
DPP-4-IN-3 is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV), exhibiting an IC50 value of 0.75 nM. This compound demonstrates significant antioxidant properties alongside insulinotropic activity, making it a valuable tool for diabetes research and the study of metabolic disorders. Its ability to modulate the DPP-IV pathway underscores its potential in therapeutic applications aimed at enhancing glucose homeostasis. -
DPPH Scavenger
2,4,7-Trihydroxy-9,10-dihydrophenanthrene is a dihydrophenanthrene derivative primarily targeting DPPH radicals. It exhibits significant antioxidant activity, with an IC50 value of 16.2 μM in DPPH radical-scavenging assays. This compound is useful in research applications focused on antioxidant mechanisms and the study of natural products derived from Pholidota chinensis Lindl. -
DPP4 Inhibitor
Evogliptin tartrate is an orally active DPP4 inhibitor that exhibits significant and sustained hypoglycemic effects in murine models. It not only lowers blood glucose levels but also attenuates the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. This compound is suitable for research applications related to type 2 diabetes, osteoporosis, renal impairment, and chronic liver inflammation. -
DPP IV/CA Inhibitor
DPP IV/hCA II-IN-1 is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) enzymes. This compound exhibits a strong inhibitory effect on DPP IV with an IC50 value of 0.049 μM, while displaying varying Ki values for different carbonic anhydrase isoforms, including 0.0361 μM for CA II. Its dual-target inhibitory activity makes it a valuable tool for studying metabolic disorders and exploring therapeutic avenues in conditions involving DPP IV and CA dysregulation. -
DPP-4 Inhibitor
Gemigliptin tartrate is a selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), demonstrating an IC50 of 10.3 nM for human recombinant DPP-4. This compound exhibits significant anti-glycation properties, making it valuable for research into advanced glycation end products (AGEs) and their associated diabetic complications. Its specificity and efficacy position Gemigliptin tartrate as a useful tool in studies aimed at understanding and mitigating the effects of diabetes-related conditions. -
DPP-4 Inhibitor
Saxagliptin hydrochloride is a potent, selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an inhibition constant (Ki) of 0.6-1.3 nM. This compound is primarily employed in research focused on type 2 diabetes mellitus, as it enhances insulin secretion by increasing incretin levels, aiding in glucose regulation. Saxagliptin hydrochloride serves as a valuable tool for studying DPP-4's role in glucose homeostasis and potential therapeutic interventions in diabetes management. -
DPP-4 Inhibitor
Retagliptin is a selective, competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) known for its oral bioavailability. It plays a crucial role in increasing incretin levels, which enhances insulin secretion and lowers glucagon levels in patients with type 2 diabetes mellitus (T2DM). This compound is valuable for research applications focused on the regulation of glucose homeostasis and the therapeutic potential in metabolic disorders. -
DPP-4 Inhibitor
Cofrogliptin is a potent oral dipeptidyl peptidase-4 (DPP-4) inhibitor. It exhibits long-acting antidiabetic efficacy, making it a promising candidate for the management of type 2 diabetes mellitus (T2DM). Cofrogliptin's mechanism of action enhances incretin levels, which supports insulin secretion and regulates glucose metabolism. This compound is valuable for research applications focused on diabetes treatment and metabolic disorders. -
DPP-4 Inhibitor
Sitagliptin fenilalanil is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor that plays a crucial role in the regulation of glucose metabolism. By blocking the activity of DPP-4, it increases levels of incretin hormones, which enhance insulin secretion in response to meals and reduce glucagon levels. This compound is primarily utilized in diabetes research to explore therapeutic strategies for improving glycemic control and understanding the mechanisms of insulin regulation. -
DPP IV Inhibitor
Diprotin B is an inhibitor of dipeptidyl peptidase IV (DPP IV). By exhibiting competitive inhibition, Diprotin B mimics substrate behavior due to its tripeptide structure, particularly the presence of a proline residue at the penultimate position. This compound is utilized in research to study the modulation of glucose metabolism and to explore potential therapeutic applications in diabetes and related metabolic disorders. -
DPP-4 Inhibitor
Fotagliptin benzoate is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 value of 2.27 nM. It demonstrates a favorable safety profile in both rat and canine models. This compound is primarily utilized in research related to Type 2 diabetes mellitus, providing insights into glucose metabolism and potential therapeutic interventions. -
DPP1 Inhibitor
Propyl-GSK-2793660 hydrochloride is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound demonstrates significant inhibition of DPP1 activity, making it a valuable tool for investigating mechanisms related to bronchiectasis. Its application in research may facilitate the understanding of DPP1's role in various biological processes and potential therapeutic avenues.
